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cancer  centers.  In this  review  based  on  official  recommendations  of  different  international  societies,  but
also  on  local solutions  found  in  different  expert  large-volume  centers,  we discuss  the  changes  that  need
to  be  done  for the  organization,  safety,  and  patient  management  in  interventional  oncology.  A literature
review  of  potential  solutions  in  a  context  of  scarce  anesthesiologic  resources,  limited  staff  and  limited
access  to hospital  beds  are  proposed  and  discussed  based  on  the literature  data.
©  2020  Société  franç aise  de  radiologie.  Published  by  Elsevier  Masson  SAS. All rights  reserved.. Introduction
The recent outbreak of the COVID-19 pandemic has deeply
mpacted the health organizations around the world [1]. Large
nstitutions and even cancer centers have reoriented their clinical
ctivity to accommodate the large number of patients with respi-
atory distress related to COVID-19 pneumonia. In many countries,
fficial recommendations from authorities have asked to cancel
on-urgent clinical activities and elective surgery, and reduce out-
atient clinic visits. Some centers have even turned their operating
heater to intensive care units and mobilized young oncologist
or working in the intensive care unit (ICU) [2]. In Europe and in
orth America, there are no clear data on how long this crisis will
Abbreviations: AASLD, American Association for the study of liver diseases;
EGP, aerosol generating procedure; ASCO, American Society of Medical Oncology;
CLC, Barcelona Clinic Liver Cancer staging; CIRSE, Cardio-Vascular and Interven-
ional Radiology Society of Europe; CT, computed tomography; EASL, European
ssociation for the study of the liver; ESMO, European Society of Medical Oncology;
CC, hepatocellular carcinoma; ICU, intensive care unit; IO, interventional oncology;
R,  interventional radiology; MDTB, multidisciplinary tumor board; NHS, National
ealth Service; OS, overall survival; PPE, personal protective equipment; RCC,
enal cell carcinoma; RFA, radiofrequency ablation; rt-PCR, reverse transcription
olymerase chain reaction; SIRT, radio-embolization; TACE, transcatheter arterial
hemoembolization.
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E-mail address: Alban.Denys@chuv.ch (A. Denys).
ttps://doi.org/10.1016/j.diii.2020.04.005
211-5684/© 2020 Société  franç aise de radiologie. Published by Elsevier Masson SAS. Allimpact cancer patient care and many physicians are concerned by
the “distraction effect” of the pandemic on the continuous care of
cancer patients [3]. In this unique situation, cancer patient man-
agement is particularly complex and one must balance the risk of a
delayed cancer diagnosis or potentially curative treatment against
the obvious risk of COVID-19. On the other hand, management of
resources allocated to cancer care such as general anesthesia avail-
ability, nurses and medical staff shortage either for medical leave
or reallocation may  be limited. This means that triage measures
must be appropriately taken and, in this context, some interna-
tional cancer societies have issued some recommendations that we
want to summarize and adapt here for interventional oncology (IO)
patients. Based on our local experience and on a recent review of
cancer guidelines issued by the European Society of Medical Oncol-
ogy (ESMO), the American Society of Medical Oncology (ASCO) and
the Cardio-Vascular and Interventional Radiology Society of Europe
(CIRSE).
2. Evidence on the impact of COVID-19 on cancer patients
Liang et al. reported that 1% out of 1590 patients hospitalised for
COVID-19 pneumonia had a cancer medical record and a median
age of 63 years. Moreover, patients with a cancer record had a more
severe form of COVID-19 that those without cancer (7/18 [39%]
vs. 124/1572 [8%], respectively; P = 0.0003). Patients with history
of surgery or chemotherapy in the months before COVID-19 have
 rights reserved.






























































Procedures at risk for staff exposure in patients with COVID-19.
Exposure during
anesthetic procedures
Procedure at risk of biologic liquid
exposure (bronchial expectoration,
digestive liquid or blood)
Patient requires
intubation/extubation
Patient is receiving a
form of ventilatory
support associated









Lung tumor thermal ablation
Thoracentesis
Pleural drainage




Nasogastric tube or orogastric tube
placement
Any procedure requiring nasogastric
tube placement (gastrostomy or
junostomy)
Gastrointestinal stent placement48 A. Denys et al. / Diagnostic and Inte
reater risk of developing severe disease (odd ratio [OR]: 5.34; 95%
I: 1.80 - 16.18; P = 0.0026) [4].
In another retrospective cohort in the city of Wuhan in China,
ut of 12 patients diagnosed with COVID-19, 66% were older than
0 years and 58.3% had non-small-cell lung cancer [5]. Interest-
ngly only 42.7% were on active treatment (including chemotherapy
ith or without immunotherapy or radiation therapy). Regarding
he outcome, 3/12 patients had serious illness, 1/12 required ICU
evel care, and 3/12 died [5]. Zhang et al. identified that the recent
se of anticancer therapies in the 14 days before COVID-19 such
s chemotherapy, radiotherapy and surgery was an independent
redictor of death or severe events with a hazard ratio greater
han 4. The patients aged over 60 years had higher incidence of
OVID-19 infection (4.3% vs. 1.8%, respectively) [6]. Furthermore,
n cancer patients the risk of COVID-19 when compared to the
eneral population is increased by 3 times, the risk of severe is
ncreased by 5 times, and the risk of death is increased by 8 times
6]. These findings have led the oncological groups to issue some
autiousness-raising recommendations. On the other side the risk
aken by patients with postponed potentially curative options, or
ven palliative treatments has not been established yet for obvious
easons.
. Reorganizing the IO clinic
The IO clinic activities encompass participation in multidisci-
linary tumor boards (MDTB) meetings, running IO clinic for new
atients and; treatment follow-up. The exceptional circumstances
f the ongoing pandemic call for an urgent revision of the IO clinic’s
rganization. The official ESMO recommendations recommenda-
ion for COVID-19 pandemic web-page (https://www.esmo.org/
ewsroom/covid-19-and-cancer/q-a-on-covid-19), do not refer to
he organization of MDTB. However, Cortiula et al. insist on the risk
f the so-called “distraction effect” on cancer patients outcome [3].
t is recommended to maintain a weekly MDTB meeting with one
pecialist per specialty with discussion limited to patients requir-
ng critical decisions only; MDTB meeting should be held in rooms
llowing for social distancing. Up to now, this strategy has been
argely adopted by our institutions and makes sense for patient
anagement. In addition, we recommend the creation of an organ-
pecific task force composed by the same specialists participating in
DTB that meet virtually or physically on a regular basis to define
ocal guidelines for patients’ management; these guidelines should
e adapted to the situation/conditions of each institution in order
o reduce patient and staff exposure.
The IO outpatient clinic itself has to be reorganized based on
he 3 types of visits: the new patients; the follow up for clinical and
aboratory evaluation; and the follow up with imaging. The critical
oint is that all types of patients should visit the clinic only when it
s indispensable, meaning that we should screen all the follow-up
atients in order to verify the necessity of their visit based on the
ational or regional guidelines in force. Telemedicine consultation
n this setting has gained popularity; and it can be used in many
ifferent ways [7]. The patients with organized appointments for
 consultation or an IO procedure should be informed that in case
f infection symptoms instead of coming at the in- or out-patient
linic they rather get at the relevant department for testing the day
efore. At present, a major problem is that testing patients is time-
onsuming. Even rapid tests performed directly on site, that need
ess than two and a half hour to obtain the results (measured from
he time the sample is taken to the time the result arrives), pose genuine organizational problem as we are facing a disease with
igh prevalence of asymptomatic carriers, meaning that numerous
atients require testing, and lack of isolated space for those waiting
or their results.Bone screwing or bone biopsy using
high velocity device
Furthermore, the establishment of a database of our oncologic
patients tested positive for SARS-Cov-2 and staying at home is an
important matter for monitoring purposes. The creation of a post
of a contact person to call the patients every 24/48 hours in order
to verify their general condition and give them advice about when
they need to go to the emergency department, is required. This
service is of crucial importance for aged patients living alone who
do not have either access to internet. These new practices raise
several new issues inter alia relating to ethics, privacy, and billing.
4. Patient and staff safety measures
The CIRSE has already issued some practical and useful guide-
lines for interventional radiology (IR) service during the COVID-
19 pandemic (https://www.cirse.org/wp-content/uploads/2020/
04/CIRSE APSCVIR COVID19 Checklist.pdf). We  will not reproduce
here the long list of measures proposed by the CIRSE but we  would
like to insist on some particular aspects of them that do impact
significantly our practice in IO.
4.1. Identify aerosol generating procedure (AEGP)
Many IO procedures involve general anesthesia and intubation
and extubation are recognized risks for AEGP [8]. Similarly, all
procedures at risk of coughing, as well as all procedures needing
insertion of a nasogastric tube or using high speed device as used
for bone biopsies are at risk of aerosol. Indeed, the use of jet ventila-
tion for percutaneous thermal destruction has been abandoned in
the context of COVID-19 [9]. It can be replaced by simple techniques
available on any ventilation system such as repeated apnea or low
tidal-volume ventilation (i.e., tidal volume between 3 to 4 mL/kg,
320 mL/min minimum; Respiratory rate adjusted to maintain the
end tidal carbon dioxide between 35 and 45 mmHg) which can be
used to strongly limit liver movements [10].
The use of laryngeal mask anesthesia is not indicated neither
due to the risk of air leaks and team exposure as recommended
by the Société Francaise d’Anesthésie et de Réanimation (https://
sfar.org/propositions-pour-la-prise-en-charge-anesthesique-dun-
patient-suspect-ou-infecte-a-coronavirus-covid-19/).
4.2. Identify procedures at risk for virus exposureIn patients suspect for or with confirmed COVID-19, exposure to
biological liquids should be reduced as much as possible (Table 1).
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hermal ablation during which the patient is at risk of hemopty-
is with severe coughing are at risk. Any procedure that requires
asogastric tube placement (i.e., gastrostomy or gastro-intestinal
tent placement) is similarly considered at risk. The following list is
dapted from the Society of Interventional Radiology (SIR) website
nd is of course not exhaustive.
.3. When and how to screen for COVID-19?
Screening for COVID-19 patients coming for IO procedure would
ake sense. It carries some practical difficulties that are not easy to
ddress. Since the hospital stay is aimed to be as short as possible, a
apid testing with reverse transcription polymerase chain reaction
rt-PCR) with a response within less than hour would make sense
ut are not readily available in many institutions. In the absence
f available tests, the personal protective equipment (PPE) mea-
ures must be taken as previously described. The availability of
ngio-computed tomography (CT) systems is increasing [11]. Given
he high sensitivity of angio-CT as compared to rt-PCR, those who
ave angio-CT equipment should probably perform chest CT exam-
nation before any IO procedure, especially for patients requiring
ntubation [12].
. Working with scarce resources of general anesthesia
The requisitioning of anesthesiologist teams to work in the
ntensive care units in many countries has led to shortage of anes-
hesiology resources during the pandemic in many large centers
80% reduction in the CHUV for instance). There are alternative
olutions to general anesthesia and recently alternative or comple-
entary solutions to simple sedations have been proposed such
s thoracic paravertebral block [13,14]. The infiltration of par-
vertebral nerves of tbl7 tbl8 and T9 allows the blockade of the
ympathetic liver innervation but not the parasympathetic from
he vagus nerve [13]. A double-blind study comparing sedation
nd local anesthesia associated of not to sham injection or par-
vertebral block nerve using 12.5 ml  of bupivacaine 0.5% at each
evel, found a significant reduction of the pain assessed by pain
nalog scale (VAS) analysis during and after the procedure [13].
o patient required salvage general anesthesia in the experimen-
al arm while it was necessary in 7/33 patients in the control arm
13]. The benefit persisted on patient discharge as well. Isolation
f the diaphragm during thermal ablation of sub diaphragmatic
iver tumors is also potentially useful since it reduced signif-
cantly the 24 hours cumulative dose of morphine by a factor
f 20 [15]. One other option for liver [16,17] or lung [18,19]
umors ablation is to use cryotherapy instead of radiofrequency
blation (RFA) or microwave ablation. Although this method has
een less reported than thermal hot ablation techniques, this
ethod has the advantage of being painless during treatment.
owever, it carries the risk of bleeding and tumor seeding along
he needle tract since it cannot be ablated during withdrawal
f treatment applicators [20]. Of course, substitution of curative
blation techniques by less invasive out-patient procedure like
adio-embolization (SIRT) can also be discussed. There are no
andomized data comparing thermal ablation and SIRT, however
adiation segmentectomy can provide local tumor control and 55%
-years survival in cirrhotic patients with localized hepatocellular
arcinoma [21]. This alternative is very well tolerated and limits
he risk of short-term complications and secondary visits in the
OVID-19 context.onal Imaging 101 (2020) 347–353 349
6. Disease specific approach to patient triage
6.1. Colon cancer metastases
According to the French national recommendations, for treat-
ment of digestive cancer during COVID-19 pandemic, it is not
recommended to totally discontinue surgery and interventional
therapies but to adapt practice to the context of COVID-19 [22].
Poly-chemotherapy, extensive surgery, and some targeted thera-
pies are responsible for major decrease in immunity. On the other
hand, local therapies, such as thermal ablation, induces induce low
decrease in immunity if any, with then probably no risk of increas-
ing the viral infection risk and severity, as far as patient coming to
the hospital are correctly protected and stay as short as possible.
Moreover IO treatments have a low risk of post-treatment adverse
events that might require long stay in hospital or access to post-
operative intensive care. Thus French national recommendations,
for treatment of digestive cancer during COVID-19 pandemic state
that “when possible, for lesion smaller than 3 cm and liver metas-
tases, percutaneous thermal ablation that uses less or no intensive
care or post-operative care resources and allows for very short hos-
pital stay should be favored” [22]. For oligometastatic patients with
a small tumor burden and a possible curative intent, the treatment
must not be delayed, and they must be treated with short hospital
stay, ideally as an out-patient procedure. Extensive liver resection
will probably be delayed due to the possible lack of post-operative
intensive care resources, but in some patient who  require very
extensive liver resection “liver preparation” before surgery with
IO (i.e., preoperative portal vein embolization, portal vein depriva-
tion, and pre-operative biliary drainage) can be performed. In such
patient performing these radiologic procedures as early as possible
will not place the patient at high risk, and will avoid him to queue
up on the waiting list of patients scheduled for the end of outbreak
restrictions and make him ready for surgery as soon as it will be
possible in regards to other limitations.
On the other end of the spectrum of the colorectal cancer disease
is multi-metastatic patient after failure of chemotherapy including
both oxaliplatin and irinotecan and possibly anti-antiangiogenics
also called “third line chemotherapy patient”. Recommendations
from the French group is that in front of in the absence of clear or
major benefit, interruption of such third line treatment has to be
discussed with the patient [22]. SIRT may  be a possible option in
this patient because it can provide a third line therapy treatment
with only two  short visits in the hospital, Of course any treatment
adjustment must be discussed during MDTB meetings.
6.2. Hepatocellular carcinoma (HCC)
As mentioned in the recent European Association for the study
of the liver EASL-ESCMID recommendations, it remains impor-
tant to maintain care of patients with chronic liver disease and
to identify potential ways to prioritize care of these patients in
the era of limited healthcare resources [23]. Care should be main-
tained according to the guidelines but interventional radiologists
must take into account this very uncommon context. However
access to liver transplantation, extensive liver resection or new
drugs through protocols have been stopped in this particular
situation.
In that unique context of scarce resources of both surgery and
newest systemic therapies, IO should gain a leading role to cure
or at least to control HCCs. We are used to recommend and follow
evidence-based medicine in IO but in the COVID-19 context such
data are not yet available. The common medical sense must rather
apply and one rule should guide us: prevent any loss of chance for
the patient. That being said, our responsibility is to maintain high-
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ospital resources. The COVID-19 pandemic results in unusual allo-
ation of healthcare resources. It is certainly not the appropriate
ime to try new techniques or new materials we are not used to,
ut rather to optimize what we already master, to avoid degrading
ncological results or causing more complications.
As recommended by the American Association for the study of
iver diseases AASLD (www.aasld.org):
outpatient visits must be restricted to patients who must be seen
in person, even in areas without significant COVID-19 spread. This
applies for IR consultations before treatment and for follow-up;
continue usual surveillance imaging in patients with HCC if pos-
sible. Ideally, these patients should not wait until the pandemic
abates to undergo imaging because the prospective duration of
the pandemic is unknown. Based on patient and facility-based
circumstances, an arbitrary delay of 2 months is reasonable;
proceed with HCC treatments rather than delaying them due to
the pandemic.
In patients with HCC and proven COVID-19, locoregional thera-
ies should be postponed until recovery.
.2.1. Percutaneous thermal ablation
According to last EASL recommendations, radiofrequency abla-
ion (RFA) is the standard of care for patients with Barcelona
linic Liver Cancer staging (BCLC) 0 or A tumors, not suitable for
urgery [24]. Therefore, ablation should be favored for small HCCs
i.e., < 3 cm)  all the more so as liver ablation is usually a short pro-
edure, with short hospital stay and very few complications [10]. In
R teams used to multi-bipolar RFA, the threshold can be extended
p to 5 cm tumors with excellent oncological results [25,26].
Except extreme situations where minimal resources are not
vailable anymore, there is no reason to postpone ablations to
revent any drift from curative to palliative care. For those who
re used to cryoablation of tumors outside the liver, it can be
n interesting option to use cryoablation to treat HCCs under
ocal anesthesia in order to spare anesthesia resources. Oncological
esults of cryoablation seem comparable to those of RFA [17].
French recommendations stipulate that thermal ablation of liver
umors (and especially HCC) should be used as often as possi-
le while keeping validated indications (1-3 nodules, < 3 cm,  < 5 cm
ith advanced techniques such as multi-bipolar thermal ablation)
22].
.2.2. Transcatheter arterial hemoembolization (TACE)
TACE still represents the mainstay of treatment in BCLC B
atients. However, TACE is considered as a palliative treatment,
eaning that the main objective is to control the tumor as long
s possible. Among factors of TACE heterogeneity, time intervals
etween sessions may  vary from 4-12 weeks [27,28]. With the
bjective of keeping the patient at-home as long as possible espe-
ially in quarantined areas and sparing hospital resources, some IRs
ay  consider to postpone TACE sessions.
To try to bring up a rationale, it is interesting to look at HCC
rowth pattern. Though heterogeneous, median HCC doubling-
ime was 229 days (IQR: 89-627) in a Western series of 242 HCC
atients [29]. Indolent growth was mainly observed in large tumors
OR = 1.15) with serum alfa-fetoprotein level < 20 ng/mL (OR = 1.9)
nd was more frequent in non-viral than in viral cirrhosis (50.9%
s. 32.1%, respectively) [29]. Postponing TACE for large tumors with
ow serum alfa-fetoprotein level in a context of non-viral cirrhosis
s probably acceptable if necessary, while keeping in mind that we
o not know the crisis duration.
Only 19% of patients undergo TACE as an outpatient procedure
28]. As for thermal ablation, it is desirable to limit patient’s hospital
tay. One major reason to keep the patient at hospital is to manageonal Imaging 101 (2020) 347–353
symptoms following TACE and especially the post-embolization
syndrome. It has been shown in a randomized placebo-controlled
trial that dexamethasone effectively reduce the occurrence of the
post-embolization syndrome [30]. Short dexamethasone therapy
(3 days) should be administered in TACE patients except those
with contraindication (mainly uncontrolled diabetes mellitus) in
order to lower post-TACE symptoms allowing a reduction of hospi-
tal duration. Except COVID-19 patients in the late phase (for whom
TACE should be postponed), no warning against short-exposure of
corticosteroids has been raised in the current context so far [31].
6.2.3. SIRT
In BCLC B patients, SIRT provides similar overall survival (OS)
as compared to TACE but longer time to progression [32]. Fur-
thermore, it is associated with fewer changes in liver function as
compared with chemo-embolization [33]. In addition, the work-up
phases for SIRT are routinely performed as outpatient procedures,
especially when radial access or closure devices are used. However,
this must be balanced against the need for two separated proce-
dures (work-up and treatment) per SIRT treatment, explaining that
TACE might be preferred.
In BCLC C patients and especially those with portal vein inva-
sion, sorafenib is the only recommended and still available systemic
treatment. Other systemic treatments under investigation in clin-
ical trials are no longer available in most countries during the
COVID-19 pandemic. Although randomized phase III trials reported
no benefit for SIRT over sorafenib, the concept of personalized
dosimetry has emerged and has been recently endorsed in IR
recommendations [34]. With personalized dosimetry, OS  can be
considerably extended in selected patients as shown in a retrospec-
tive analysis with propensity-score matching (26.2 vs. 8.7months)
[35].
Finally, for limited HCC disease (i.e., segmental), it has recently
been proposed to eliminate the work-up phase because lung shunt
fraction is negligible and great dose can be achieved anyway,
thereby reducing time-to-treatment and number of procedures
[36]. This option should be considered in the COVID-19 context
for tumors that are not treatable with thermal ablation.
6.3. Lung metastases and primary lung tumors
Among cancer patient infected with COVID-19, lung cancer
appears as the most frequent primary cancer. Indeed in a series
of 28 COVID-19 cancer patients, lung cancer was the most fre-
quent cancer (25%), with 53.6% of patients having severe events and
mortality of 28.6% [12]. In this series, a last anti-tumor treatment
within 14 days, including chemotherapy (10.7%), radiotherapy
(3.6%), targeted therapy (7.1%) and immunotherapy combined with
chemotherapy (3.6%), significantly increased the risk of develop-
ing severe events (HR = 4.079; 95% CI: 1.086-15.322; P = 0.037) [12].
Rapid death from COVID infection has been reported in a patient
withnon small cell lung cancer favorably controlled with nivolumab
before the infection [37].
The National Health Service (NHS UK) warned that individuals
who are undergoing active chemotherapy or radical radiotherapy
for primary lung cancer, are particularly vulnerable to serious ill-
ness if they become affected by COVID-19 [38]. In addition several
factors/co-morbidities are likely to be linked with a poorer prog-
nosis with coronavirus including age over 60 years, pre-existing
cardiovascular disease and pre-existing respiratory disease. Thus it
is advisable to avoid any biopsy or lung thermal ablation in patients
with the above-mentioned comorbidities, which are quite frequent
in the primary non-small cell lung cancer population.
Patients in good general condition with none of the above
described comorbidities but who  have lung metastases and can
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ust be prioritized as level 1 according to NHS clinical guide for the
anagement of non-COVID-19 patients requiring acute treatment
38]. They can be classified as prioritized as well because elective
urgery/ablation with the expectation of cure must be performed
ithin 4 weeks to save life/progression of disease beyond oper-
bility. It has been demonstrated that size and safety margins are
rognostic factors of successful lung thermal ablation [39], and that
edian overall survival after lung ablation is beyond 5 years [40].
icrowave ablation seems to induce less pneumothorax than RFA
41]. Furthermore, the risk of prolonged intensive care is moder-
ted when patient have a lung parenchyma without underlying
isease even if the possibility of admission in such unit has to be dis-
ussed according the general status of the hospital. A downstream
ospitalization solution must be defined in case of pneumotho-
ax. According to anesthesiology resources, it might be needed to
elect therapy that can be delivered with minimal sedation or only
eneral anesthesia, for example selecting cryoablation over RFA or
icrowave.
.4. Kidney cancer treatment
The incidence of renal cell carcinoma (RCC) has steadily
ncreased in Europe in the last 2 decades, with stage I tumors
ow accounting for 40% to 50% of new patients. Up to 75%
f these small RCC are found incidentally on ultrasound or
ross-sectional imaging performed for another reason, and approx-
mately 50% of patients are now older than 65 years, and carry
isk factors of RCC such as smoking, obesity and hypertension
42]. These comorbidities, along with the renal function, are
ey factors when determining the best treatment strategy. The
verdiagnosis of incidentally detected small RCC could lead to
vertreatment. In response to the changes in the epidemiology of
CC, nephron-sparing techniques have taken a prominent place in
he management of these small renal masses to reduce the risk of
hronic kidney disease. The guidelines now include the four con-
emporary approaches to the management of small renal masses to
e discussed during the tumor board: partial nephrectomy, radical
ephrectomy, ablative therapies and active surveillance, depend-
ng on patients’ condition and tumor characteristics [43,44].
During COVID-19 pandemic, many hospitals are now recom-
ending cancellations of elective surgeries. In order to clarify the
ague term “elective”, Stensland et al. proposed a triage of uro-
ogic surgeries, taking advantage of the lessons learned from Asian
ountries [45]. They recommend that surgery should not be delayed
or cT3+ tumors, including all patients with renal vein and/or infe-
ior vena cava thrombi. In order to spare ventilators and inpatient
tay, they suggest that planned partial or radical nephrectomy for
T1 masses should be delayed, and IO ablative approaches should
e considered in selected patients. In this perspective, cryoabla-
ion has the advantage of being feasible under conscious sedation
r even local anesthesia due to its intrinsic anesthetic properties
46]. In addition, a short hospital stay is associated with IO abla-
ive techniques, some procedures being done on an outpatient
asis. However, the best candidates for non-surgical therapies are
atients carrying several comorbidities. Admitting these patients
n hospitals will leave them at greater risk for COVID-19.
Decision for treating patients must refer to the natural his-
ory of RCC. Small renal tumors have variable growth rates with
 mean growth of 0.31 cm/year in the largest multicenter analy-
is [47]. A substantial number of small renal masses have a slow
rowth and some have zero growth under surveillance [48]. In a
ohort of 457 patients with 544 renal masses followed for at least 5
ears, the median overall linear growth rate was  1.9 mm/year and
pproximately one-third of their patients crossed over to delayed
ntervention [48]. Most of these patients were likely to do so within
he first 2–3 years on active surveillance [48]. These findings showonal Imaging 101 (2020) 347–353 351
that postponing a renal tumor ablation is a safe oncologic practice.
Cancer specific mortality will not be affected by a delay of weeks
or even months before doing thermal ablation of eligible patients.
These patients can safely remain in active surveillance as long as
the COVID-19 pandemic lasts.
6.5. Palliative pain procedures
IO has now an increasing role in pain palliation. Percutaneous
osteosynthesis and cementoplasty can be proposed to patient with
bone metastases [49,50] [51–53]. Even if according to NHS guide,
“Palliative radiotherapy where alleviation of symptoms would
reduce the burden on other healthcare services, such as hemopty-
sis” is classified as a level 4 radiotherapy of priority on a scale from
1 to 5, and classified as a level 5 priority on the 1 to 6 scale level for
of categorization of cancer patients inside of “curative therapy with
a high (>50%) chance of palliation/temporary tumor control but < 1
year life extension” there is no mention of pain in this guide [38].
However, pain palliation must be considered as an integrated part
of cancer treatment, as underline by the French «Plan cancer»  [54].
For this reason we keep trying to treat pain in oncologic patients
during COVID-19 pandemic. Once again pain treatment is beneficial
to oncologic patients due to the possibility to treat patient in a single
day hospital with very minor risks of prolonged hospitalization or
need for intensive post-treatment care. The shortage in anesthetic
resources including drugs such as curare and hypnotics lowers our
access to general anesthesia and rachi-anesthesia is a very efficient
surrogate to general anesthesia in the population of patients with
painful pelvic bone metastases who  can benefit from percutaneous
osteosynthesis [50]. Short acting drug allows for treating a patient
in the morning and discharge him on his feet in the late afternoon.
Moreover these short acting drugs are not needed for treatment of
COVID-19 patient ventilated in the ICU.
Preventive cementoplasty or osteosynthesis [51,52] in non-
painful patients with impeding fractures has to be discussed on
a specific patient basis. The patient should avoid any activity that
increases the risk of fracture, which is probably easier to follow in
these times of containment.
6.6. Biopsies
Biopsy of superficial organs must not be delayed when they are
needed for a definite diagnosis that will decide for treatment. Deep
abdominal biopsy carries a low risk of complication and must be
performed when needed to decide for treatment strategy. At last,
when compared to other deep organ biopsy, lung biopsy carries
the specific risk of pneumothorax and the decision to expose the
patient to a prolonged hospital stay must be weighted in front of the
benefit of early diagnosis. Both clinical and technical considerations
must be balanced and discussed with the patient and multidisci-
plinary tumor board [55]. The benefit of an early diagnosis with
possible access to a curative treatment must push toward no delay
in biopsy. On the other hand, severe emphysema, a small, deep
lesion, pre-existing comorbidities, a long trans pulmonary path and
all factors known to increase risks and severity of pneumothorax
must be discussed. Technically, an access with no transpulmonary
path must be preferred if possible. Any countermeasure to pneu-
mothorax such as opposite position immediately after biopsy, or
even better side decubitus at the time of the biopsy with biopsied
lung down are recommended [56,57]. In addition, the use of blood
patch [58,59] or gelatin sponge slurry [60] or even normal saline
tract sealant [58] are effective countermeasure to pneumothorax
and chest tube placement. Overall, after 3 weeks of COVID-19 pan-
demic, our lung biopsy program has been maintained to 70% of
our usual practice avoiding biopsy in patients with emphysema
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or patients requiring biopsy to enter clinical trial or precision
edicine studies. Decisions must be discussed with the patient and
uring MDTB meetings taking into account the actual benefit. For
ach of these diseases it is recommended to consider tumor growth
ate as established on imaging and the risk of delayed treatment.
. Conclusion
Among surgery and IR departments, IO is the one that keeps
he highest degree of activity. This activity is due to the essen-
ial role of biopsies, thermal ablations and palliative treatments
uch as cementoplasty and osteosynthesis. This is due to the low
nvasiveness of these procedures that require little post-treatment
esources. This highlights the pivotal role played by IO in cancer
reatment even during the COVID-19 pandemic.
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